DIAGNOSTIC CRITERIA

RECOGNIZING B.E.D. SYMPTOMS IN ADULTS

Hypothetical provider and patient portrayals. Individual results may vary.

B.E.D. is the most common eating disorder in US adults^*1

It’s more prevalent than bulimia nervosa (BN) and anorexia nervosa (AN) combined.^*1,2

Drug treatment is not indicated for all adult patients with B.E.D.

*Estimated 12-month and lifetime prevalence among an eating disorder–assessed subsample (n=2,980) of the National Comorbidity Survey Replication, a nationally representative face-to-face household survey of English-speaking adults aged ≥18 years.^1,2

^†In an Online survey conducted in 2013 of 22,397 US adults aged ≥18 years, 344 met DSM-5^@criteria for B.E.D. (Level of severity not specified).

Yes, there can be a stigma that surrounds having B.E.D., but people with B.E.D. are worth the discussion. Both patients and healthcare professionals need to educate themselves and talk openly about it.

— Ryan, diagnosed with moderate B.E.D. and treated with Vyvanse

Ryan, a real patient treated with Vyvanse®.

B.E.D. may go undiagnosed

In an online survey of 22,397 US adults, 344 met DSM-5^® diagnostic criteria for B.E.D. in the past 12 months (level of severity not specified). Of those: 3.2% (11 of 344) reported ever receiving a diagnosis of B.E.D. by a healthcare provider.^†3

^†Data from a 2013 online survey of adults aged ≥18 years.³

There is no typical adult B.E.D. patient

Adults with B.E.D. represent a diverse spectrum of patient types

B.E.D. affects both men and women.¹ In US adults, B.E.D. is observed across racial and ethnic groups.^‡4,5

^‡Based on analysis of a combined data set of 3 nationally representative US samples consisting of non-Latino whites, Latinos, Asians, and African Americans.⁵

Mean age of onset

Onset of B.E.D. occurs at a later mean age compared with bulimia nervosa (BN) and anorexia nervosa (AN)^§1

Eating disorders are very personal and private and not everyone with B.E.D. looks the same. Our physiques do not always reflect what’s going on inside.

— Kabara, diagnosed with moderate B.E.D. and treated with Vyvanse

Kabara, a real patient treated with Vyvanse®.

B.E.D. is a distinct disorder

B.E.D. is distinct from obesity and overeating. Although B.E.D. can be associated with increased weight, it occurs in normal-weight, overweight, and obese adults.^§1

The majority of adults with B.E.D. are not obese^||1

^§Data (based on Version 3.0 of the World Health Organization Composite International Diagnostic Interview and DSM-IV^® criteria) from an eating disorder-assessed subsample (n=2,980) of the National Comorbidity Survey Replication (NCSR), a nationally representative face-to-face household survey of English-speaking adults aged ≥18 years.¹
^||Current body mass index (BMI) in adults with 12-month prevalence of B.E.D. among the NCSR survey population detailed above.¹
BMI=body mass index.

B.E.D. vs Overeating

While overeating is a challenge for many Americans, recurrent binge-eating is much less common and far more severe.⁶

DSM-5^® diagnostic criteria for adults with binge eating disorder (B.E.D.)⁴

To be diagnosed with B.E.D., individuals must meet the following criteria adapted from the DSM-5^®:

Recurrent episodes of binge eating characterized by `both` of the following:

Consuming an abnormally large amount of food in a short period of time compared with what others might eat in the same amount of time under the same or similar circumstances

Experiencing a loss of control over eating during the episode

Episodes feature `at least 3` of the following:

Consuming food faster than normal

Consuming food until uncomfortably full

Consuming large amounts of food when not hungry

Consuming food alone due to embarrassment over how much one is eating

Feeling disgusted, depressed, or guilty after the binge

Overall, there is significant distress about the binge eating.

The binge eating occurs, on average, at least once per week for 3 months.

The binge eating is not associated with regular compensatory behavior associated with bulimia nervosa and does not occur solely during an episode of bulimia nervosa or anorexia nervosa.

Diagnosis should be based upon a complete evaluation of the patient that confirms the criteria for B.E.D. established in DSM-5^®.

My doctor’s willingness to listen and to ask the right questions—and recognize my B.E.D.—made such a difference in my life.

— Parker, diagnosed with moderate B.E.D. and treated with Vyvanse

Parker, a real patient treated with Vyvanse®.

Severity of B.E.D. (based on DSM-5^®)⁴

The minimum level of severity is based on the number of binge eating episodes per week, and may be increased to reflect other symptoms and the degree of functional disability.

As embarrassed as I felt, I had a frank discussion with my nurse practitioner about my multiple binges per day and the emotions I felt before, during, and after a binge. After my medical evaluation, she diagnosed my condition as severe B.E.D.

— Kathy, diagnosed with severe B.E.D. and treated with Vyvanse

Kathy, a real patient treated with Vyvanse®.

Binge Eating Disorder Screener-7

This patient-reported screener can help you screen adults who you suspect may have B.E.D.

DOWNLOAD

Hypothetical patient portrayal.
Individual results may vary.

WHY VYVANSE FOR B.E.D. IN ADULTS

See Vyvanse clinical trial results for moderate to severe B.E.D. in adults.

EFFICACY STUDIES

ADVERSE REACTIONS

Hypothetical patient portrayal

KEEP IN TOUCH

Stay up to date with the latest information to help support your Vyvanse patients.

References

Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication [published correction appears in Biol Psychiatry. 2012;72(2):164]. Biol Psychiatry. 2007;61(3):348‐358.
Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013;73(9):904-914.
Cossrow N, Pawaskar M, Witt EA, et al. Estimating the prevalence of binge eating disorder in a community sample from the United States: comparing DSM-IV-TR^® and DSM-5^® criteria. J Clin Psychiatry. 2016;77(8):e968-974.
Adapted from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5^®). 5th ed. Arlington, VA: American Psychiatric Association; 2013;350-353.
Marques L, Alegria M, Becker AE, et al. Comparative prevalence, correlates of impairment, and service utilization for eating disorders across US ethnic groups: Implications for reducing ethnic disparities in health care access for eating disorders. Int J Eat Disord. 2011;44(5):412-420.
American Psychiatric Association. DSM-5^® Fact Sheet. Feeding and eating disorders. http://www.dsm5.org/documents/eating%20disorders%20fact%20sheet.pdf. Accessed September 8, 2020.

INDICATION AND LIMITATION OF USE

Vyvanse is indicated for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Vyvanse, other amphetamine-containing products, and methylphenidate have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

Contraindications
- Known hypersensitivity to amphetamines or other ingredients of Vyvanse. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have occurred.
- Use with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis.
Warnings and Precautions
- Prior to and during treatment assess for the presence of cardiac disease. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Sudden death, stroke and myocardial infarction have been reported in adults with CNS stimulants at recommended doses, as well as sudden death in pediatric patients with structural cardiac abnormalities and other serious heart problems while taking CNS stimulants at recommended doses. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias while taking Vyvanse.
- CNS stimulants cause increases in blood pressure (mean increase about 2-4 mm Hg) and heart rate (mean increase about 3-6 bpm). Monitor all patients for tachycardia and hypertension.
- Exacerbation of Pre-existing Psychosis: May exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Induction of a Manic Episode in Patients with Bipolar Disorder: May induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms, or a family history of suicide, bipolar disorder, and depression). New Psychotic or Manic Symptoms: At recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients with no prior history of psychotic illness or mania. Discontinue if symptoms occur.
- CNS stimulants, including Vyvanse, are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with stimulants. Further evaluation may be required, including referral.
- Increased risk of serotonin syndrome when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans) and CYP2D6 inhibitors, but also during overdosage situations. Discontinue Vyvanse if it occurs and initiate supportive treatment.
Adverse Reactions
- The most common adverse reactions (≥5% and at least twice the rate of placebo) reported in clinical trials of adults with moderate to severe B.E.D. were: dry mouth, insomnia, decreased appetite, increased heart rate, constipation, feeling jittery, and anxiety.
Pregnancy and Lactation
Other Considerations
- Safety and effectiveness in patients <18 years with B.E.D. have not been established.

Please click here for Full Prescribing Information.

VYVANSE and the VYVANSE logo are registered trademarks of Takeda Pharmaceuticals U.S.A., Inc. TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited. ©2022 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved. 1-877-TAKEDA-7 (1-877-825-3327).

All content of this website, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Takeda Pharmaceuticals U.S.A., Inc. and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or, distribution, nor may these objects be downloaded, modified, or posted to other sites. This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Terms of Use for more information. While Takeda makes reasonable efforts to include accurate, up-to-date information on this site, Takeda makes no warranties or representations as to its accuracy. Takeda assumes no liability for any errors or omissions in the content of this site. The information on this site is not intended to make a diagnosis or to take the place of talking to a US healthcare professional.

US-LIS-1285v1.0 10/22

Keep in touch

INDICATION AND LIMITATION OF USE

Vyvanse is indicated for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults. It is not for weight loss or to treat obesity. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. Click here for FULL SAFETY INFORMATION.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE: CNS stimulants, including Vyvanse, other amphetamine-containing products, and methylphenidate have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy. Click here for FULL SAFETY INFORMATION.

INDICATION AND IMPORTANT SAFETY INFORMATION

Go Back

INDICATION AND LIMITATION OF USE

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Vyvanse, other amphetamine-containing products, and methylphenidate have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

Contraindications
- Known hypersensitivity to amphetamines or other ingredients of Vyvanse. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have occurred.
- Use with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis.
Warnings and Precautions
- Prior to and during treatment assess for the presence of cardiac disease. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Sudden death, stroke and myocardial infarction have been reported in adults with CNS stimulants at recommended doses, as well as sudden death in pediatric patients with structural cardiac abnormalities and other serious heart problems while taking CNS stimulants at recommended doses. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias while taking Vyvanse.
- CNS stimulants cause increases in blood pressure (mean increase about 2-4 mm Hg) and heart rate (mean increase about 3-6 bpm). Monitor all patients for tachycardia and hypertension.
- Exacerbation of Pre-existing Psychosis: May exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Induction of a Manic Episode in Patients with Bipolar Disorder: May induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms, or a family history of suicide, bipolar disorder, and depression). New Psychotic or Manic Symptoms: At recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients with no prior history of psychotic illness or mania. Discontinue if symptoms occur.
- CNS stimulants, including Vyvanse, are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with stimulants. Further evaluation may be required, including referral.
- Increased risk of serotonin syndrome when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans) and CYP2D6 inhibitors, but also during overdosage situations. Discontinue Vyvanse if it occurs and initiate supportive treatment.
Adverse Reactions
- The most common adverse reactions (≥5% and at least twice the rate of placebo) reported in clinical trials of adults with moderate to severe B.E.D. were: dry mouth, insomnia, decreased appetite, increased heart rate, constipation, feeling jittery, and anxiety.
Pregnancy and Lactation
Vyvanse may cause fetal harm. Breastfeeding is not recommended during Vyvanse treatment.

Other Considerations
- Safety and effectiveness in patients <18 years with B.E.D. have not been established.

DIAGNOSTIC CRITERIA

RECOGNIZING B.E.D. SYMPTOMS IN ADULTS

B.E.D. is the most common eating disorder in US adults*1

It’s more prevalent than bulimia nervosa (BN) and anorexia nervosa (AN) combined.*1,2

Drug treatment is not indicated for all adult patients with B.E.D.

Yes, there can be a stigma that surrounds having B.E.D., but people with B.E.D. are worth the discussion. Both patients and healthcare professionals need to educate themselves and talk openly about it.

B.E.D. may go undiagnosed

In an online survey of 22,397 US adults, 344 met DSM-5® diagnostic criteria for B.E.D. in the past 12 months (level of severity not specified). Of those: 3.2% (11 of 344) reported ever receiving a diagnosis of B.E.D. by a healthcare provider.†3

There is no typical adult B.E.D. patient

Adults with B.E.D. represent a diverse spectrum of patient types

B.E.D. affects both men and women.1 In US adults, B.E.D. is observed across racial and ethnic groups.‡4,5

Mean age of onset

Onset of B.E.D. occurs at a later mean age compared with bulimia nervosa (BN) and anorexia nervosa (AN)§1

Eating disorders are very personal and private and not everyone with B.E.D. looks the same. Our physiques do not always reflect what’s going on inside.

B.E.D. is a distinct disorder

B.E.D. is distinct from obesity and overeating. Although B.E.D. can be associated with increased weight, it occurs in normal-weight, overweight, and obese adults.§1

The majority of adults with B.E.D. are not obese||1

B.E.D. vs Overeating

While overeating is a challenge for many Americans, recurrent binge-eating is much less common and far more severe.6

DSM-5® diagnostic criteria for adults with binge eating disorder (B.E.D.)4

Recurrent episodes of binge eating characterized by both of the following:

Episodes feature at least 3 of the following:

Overall, there is significant distress about the binge eating.

The binge eating occurs, on average, at least once per week for 3 months.

The binge eating is not associated with regular compensatory behavior associated with bulimia nervosa and does not occur solely during an episode of bulimia nervosa or anorexia nervosa.

My doctor’s willingness to listen and to ask the right questions—and recognize my B.E.D.—made such a difference in my life.

Severity of B.E.D. (based on DSM-5®)4

As embarrassed as I felt, I had a frank discussion with my nurse practitioner about my multiple binges per day and the emotions I felt before, during, and after a binge. After my medical evaluation, she diagnosed my condition as severe B.E.D.

Binge Eating Disorder Screener-7

WHY VYVANSE FOR B.E.D. IN ADULTS

KEEP IN TOUCH

References

INDICATION AND IMPORTANT SAFETY INFORMATION

B.E.D. is the most common eating disorder in US adults^*1

It’s more prevalent than bulimia nervosa (BN) and anorexia nervosa (AN) combined.^*1,2

In an online survey of 22,397 US adults, 344 met DSM-5^® diagnostic criteria for B.E.D. in the past 12 months (level of severity not specified). Of those: 3.2% (11 of 344) reported ever receiving a diagnosis of B.E.D. by a healthcare provider.^†3

B.E.D. affects both men and women.¹ In US adults, B.E.D. is observed across racial and ethnic groups.^‡4,5

Onset of B.E.D. occurs at a later mean age compared with bulimia nervosa (BN) and anorexia nervosa (AN)^§1

B.E.D. is distinct from obesity and overeating. Although B.E.D. can be associated with increased weight, it occurs in normal-weight, overweight, and obese adults.^§1

The majority of adults with B.E.D. are not obese^||1

While overeating is a challenge for many Americans, recurrent binge-eating is much less common and far more severe.⁶

DSM-5^® diagnostic criteria for adults with binge eating disorder (B.E.D.)⁴

Recurrent episodes of binge eating characterized by `both` of the following:

Episodes feature `at least 3` of the following:

Severity of B.E.D. (based on DSM-5^®)⁴